PNTG vs. LFST, PRVA, USPH, INNV, WGS, TALK, DCGO, SHCR, PIII, and EUDA
Should you be buying The Pennant Group stock or one of its competitors? The main competitors of The Pennant Group include LifeStance Health Group (LFST), Privia Health Group (PRVA), U.S. Physical Therapy (USPH), InnovAge (INNV), GeneDx (WGS), Talkspace (TALK), DocGo (DCGO), Sharecare (SHCR), P3 Health Partners (PIII), and EUDA Health (EUDA). These companies are all part of the "health services" industry.
LifeStance Health Group (NASDAQ:LFST) and The Pennant Group (NASDAQ:PNTG) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations.
85.5% of LifeStance Health Group shares are owned by institutional investors. Comparatively, 85.9% of The Pennant Group shares are owned by institutional investors. 6.6% of LifeStance Health Group shares are owned by company insiders. Comparatively, 5.8% of The Pennant Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
The Pennant Group has a net margin of 2.86% compared to The Pennant Group's net margin of -15.69%. LifeStance Health Group's return on equity of 13.42% beat The Pennant Group's return on equity.
The Pennant Group has lower revenue, but higher earnings than LifeStance Health Group. LifeStance Health Group is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks.
The Pennant Group received 24 more outperform votes than LifeStance Health Group when rated by MarketBeat users. Likewise, 44.74% of users gave The Pennant Group an outperform vote while only 26.32% of users gave LifeStance Health Group an outperform vote.
LifeStance Health Group presently has a consensus price target of $8.80, suggesting a potential upside of 53.04%. The Pennant Group has a consensus price target of $24.00, suggesting a potential upside of 0.21%. Given The Pennant Group's higher probable upside, equities analysts plainly believe LifeStance Health Group is more favorable than The Pennant Group.
LifeStance Health Group has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, The Pennant Group has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.
In the previous week, LifeStance Health Group had 5 more articles in the media than The Pennant Group. MarketBeat recorded 10 mentions for LifeStance Health Group and 5 mentions for The Pennant Group. LifeStance Health Group's average media sentiment score of 0.58 beat The Pennant Group's score of 0.57 indicating that The Pennant Group is being referred to more favorably in the news media.
Summary
The Pennant Group beats LifeStance Health Group on 13 of the 18 factors compared between the two stocks.
Get The Pennant Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PNTG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PNTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Pennant Group Competitors List
Related Companies and Tools
